Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial

Journal of Alzheimer's Disease

Volumn 56, Issue 4, 2017, Pages 1495-1504

  Jia, Jianping ^a,b   Wei, Cuibai ^a,b   Jia, Longfei ^a,c   Tang, Yi ^a,b   Liang, Junhua ^a   Zhou, Aihong ^a   Li, Fangyu ^a,b   Shi, Lu ^a,b   Doody, Rachelle S ^d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^c HENRY FORD HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Chinese population; Clinical trial; Donepezil

Indexed keywords

DONEPEZIL; PLACEBO; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHINESE; CLINICIAN INTERVIEW DATA IMPRESSION OF SEVERITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEMENTIA ASSESSMENT; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV-TR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS BRADYCARDIA; URINARY TRACT INFECTION; WEIGHT REDUCTION; CHINA; CLINICAL TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; CHINA; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MENTAL STATUS AND DEMENTIA TESTS; PIPERIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85013436256     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-161117     Document Type: Article

References (30)

1. Jia J, Wang F, Wei C, Zhou A, Jia X, Li F, Tang M, Chu L, Zhou Y, Zhou C, Cui Y,Wang Q,WangW, Yin P, Hu N, Zuo X, Song H, Qin W, Wu L, Li D, Jia L, Song J, Han Y, Xing Y, Yang P, Li Y, Qiao Y, Tang Y, Lv J, Dong X (2014) The prevalence of dementia in urban and rural areas of China. Alzheimers Dement 10, 1-9.
2. Aguero-Torres H, Qiu C, Winblad B, Fratiglioni L (2002) Dementing disorders in the elderly: Evolution of disease severity over 7 years. Alzheimer Dis Assoc Disord 16, 221-227.
3. Bullock R, Hammond G (2003) Realistic expectations: The management of severe Alzheimer disease. Alzheimer Dis Assoc Disord 17(Suppl 3), S80-S85.
4. Galasko D, Schmitt F, Thomas R, Jin S, Bennett D, Alzheimer's Disease Cooperative, Study (2005) Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc 11, 446-453.
5. Aguero-Torres H, Fratiglioni L, Winblad B (1998) Natural history of Alzheimer's disease and other dementias: Review of the literature in the light of the findings from the Kungsholmen Project. Int J Geriatr Psychiatry 13, 755-766.
6. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT (1999) The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement Geriatr Cogn Disord 10, 237-244.
7. Rogers SL, Doody RS, Mohs RC, Friedhoff LT (1998) Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebocontrolled study. Donepezil Study Group. Arch Intern Med 158, 1021-1031.
8. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group Neurology 50, 136-145.
9. Rogers SL, Friedhoff LT (1996) The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 7, 293-303.
10. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S (2007) Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 69, 459-469.
11. Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, Donepezil MSAD, Study Investigators, Group (2005) Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: A subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 20, 559-569.
12. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A, Severe Alzheimer's Disease Study, Group (2006) Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet 367, 1057-1065.
13. Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Ohbayashi T (2008) Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 25, 399-407.
14. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, DSM-IV. 4th edition, 4th text rev. American Psychiatric Association,Washington, D.C.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
16. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
17. Panisset M, Roudier M, Saxton J, Boller F (1994) Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol 51, 41-45.
18. Schmitt FA, AshfordW, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ (1997) The severe impairment battery: Concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl 2), S51-S56.
19. Olin JT, Schneider LS, Doody RS, Clark CM, Ferris SH, Morris JC, Reisberg B, Schmitt FA (1996) Clinical evaluation of global change in Alzheimer's disease: Identifying consensus. J Geriatr Psychiatry Neurol 9, 176-180.
20. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH (1997) Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl 2), S22-S32.
21. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F (2002) Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial(MMM300). Stroke 33, 1834-1839.
22. Jelic V, Haglund A, Kowalski J, Langworth S, Winblad B (2008) Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis. Dement Geriatr Cogn Disord 26, 458-466.
23. Homma A, ImaiY, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I,Koma H,TakaseT, OhbayashiT(2009) Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: Results from a 52-week, openlabel, multicenter, extension study in Japan. Dement Geriatr Cogn Disord 27, 232-239.
24. ReisbergB, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, Memantine Study G (2003) Memantine in moderate-tosevere Alzheimer's disease. N Engl J Med 348, 1333-1341.
25. Burns A, Spiegel R, Quarg P (2004) Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int J Geriatr Psychiatry 19, 243-249.
26. Wilkinson DG, Hock C, Farlow M, van Baelen B, Schwalen S (2002) Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months. Int J Clin Pract 56, 509-514.
27. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P, Donepezil Nordic Study Group (2001) A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57, 489-495.
28. MasudaY(2004) Cardiac effect of cholinesterase inhibitors used in Alzheimer's disease from basic research to bedside. Curr Alzheimer Res 1, 315-321.
29. Takaya T, Okamoto M, Yodoi K, Hata K, Kijima Y, Nakajima H, Nishikawa Y, Kita T, Ito M, Seo T, Kawashima S (2009) Torsades de Pointes with QT prolongation related to donepezil use. J Cardiol 54, 507-511.
30. Tanaka A, Koga S, Hiramatsu Y (2009) Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade de Pointes. Intern Med 48, 1219-1223.